[18F]-fluoromisonidazole (FMISO) PET/MRI hypoxic fraction distinguishes neuroinflammatory pseudoprogression from recurrent glioblastoma in patients treated with pembrolizumab is a research paper published in Neuro-Oncology Practice (2022). On theSindex it has a DataRank of 0.360. It has been cited 10 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.360
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →National Cancer Institute
Grant: 1K08CA237809-01
National Cancer Institute
Grant: 2L30CA220897-02A1
NCI NIH HHS
Grant: K08 CA237809
NCATS NIH HHS
Grant: KL2 TR002370
NCI NIH HHS
Grant: L30 CA220897
National Institutes of Health
Grant: 5K08CA237809-03
Defining the Hypoxic Immunosuppressive Microenvironment as a Biomarker of Therapy Efficacy in Glioblastoma Using Iron Oxide Enhanced FMISO PET/MRI
National Institutes of Health
Fields of Study
Keywords
Sustainable Development Goals